Holen Sie sich die Stockscreener-App
59.82
3.55%
-2.20
Handel nachbörslich:
58.50
-1.32
-2.21%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt CYTK?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$62.02
Offen:
$62.1
24-Stunden-Volumen:
2.01M
Relative Volume:
1.00
Marktkapitalisierung:
$7.31B
Einnahmen:
$18.47M
Nettoeinkommen (Verlust:
$-589.53M
KGV:
-11.37
EPS:
-5.26
Netto-Cashflow:
$-399.80M
1W Leistung:
-0.82%
1M Leistung:
-10.65%
6M Leistung:
+83.84%
1J Leistung:
+25.20%
1-Tages-Spanne:
$59.37
$62.26
1-Wochen-Bereich:
$59.37
$64.12
52-Wochen-Spanne:
$29.31
$69.33
Cytokinetics Inc Stock (CYTK) Company Profile
Firmenname
Cytokinetics Inc
Sektor
Branche
Telefon
(650) 624-3000
Adresse
350 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Vergleichen Sie CYTK mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CYTK
Cytokinetics Inc
|
59.82 | 7.58B | 18.47M | -589.53M | -399.80M | -5.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
449.52 | 115.43B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
749.79 | 78.44B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
862.05 | 52.42B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
392.10 | 51.68B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
198.46 | 42.80B | 447.02M | -1.18B | -906.14M | -6.1812 |
Cytokinetics Inc Stock (CYTK) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-30 | Fortgesetzt | Raymond James | Mkt Perform |
| 2025-04-24 | Eingeleitet | Barclays | Overweight |
| 2025-02-07 | Eingeleitet | Citigroup | Buy |
| 2025-01-22 | Eingeleitet | Stifel | Buy |
| 2024-11-08 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-08-13 | Herabstufung | Goldman | Buy → Neutral |
| 2024-01-24 | Herabstufung | UBS | Buy → Neutral |
| 2024-01-05 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2023-11-09 | Eingeleitet | Goldman | Buy |
| 2023-11-07 | Eingeleitet | B. Riley Securities | Buy |
| 2023-08-15 | Eingeleitet | SVB Securities | Outperform |
| 2023-02-17 | Eingeleitet | BofA Securities | Neutral |
| 2022-12-23 | Bestätigt | Needham | Buy |
| 2022-12-20 | Eingeleitet | Truist | Buy |
| 2022-10-11 | Eingeleitet | UBS | Buy |
| 2022-01-28 | Eingeleitet | Goldman | Buy |
| 2021-12-22 | Eingeleitet | Oppenheimer | Outperform |
| 2021-12-10 | Eingeleitet | JP Morgan | Overweight |
| 2021-10-07 | Eingeleitet | Jefferies | Buy |
| 2021-03-12 | Eingeleitet | Wolfe Research | Outperform |
| 2021-02-18 | Eingeleitet | Barclays | Overweight |
| 2021-01-20 | Bestätigt | H.C. Wainwright | Buy |
| 2020-10-29 | Eingeleitet | Goldman | Neutral |
| 2020-07-10 | Eingeleitet | Raymond James | Strong Buy |
| 2020-05-05 | Eingeleitet | Mizuho | Buy |
| 2020-04-09 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2018-09-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-09-10 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2017-11-22 | Bestätigt | Morgan Stanley | Overweight |
| 2017-11-22 | Herabstufung | Needham | Strong Buy → Buy |
| 2017-11-21 | Bestätigt | H.C. Wainwright | Buy |
| 2017-07-31 | Eingeleitet | Morgan Stanley | Overweight |
| 2017-03-08 | Eingeleitet | Rodman & Renshaw | Buy |
| 2017-02-06 | Hochstufung | Needham | Buy → Strong Buy |
| 2016-12-16 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2016-07-28 | Bestätigt | Needham | Buy |
| 2015-11-10 | Bestätigt | FBR Capital | Outperform |
| 2015-11-09 | Bestätigt | ROTH Capital | Buy |
| 2015-07-24 | Bestätigt | MLV & Co | Buy |
| 2014-12-31 | Bestätigt | ROTH Capital | Buy |
| 2014-11-04 | Hochstufung | MLV & Co | Hold → Buy |
| 2014-04-28 | Bestätigt | Needham | Buy |
Alle ansehen
Cytokinetics Inc Aktie (CYTK) Neueste Nachrichten
China approves Cytokinetics’ heart drug MYQORZO, triggering $7.5m payment - Investing.com Nigeria
Why Cytokinetics Incorporated stock is favored by top institutionsJuly 2025 Institutional & Capital Efficient Trading Techniques - Bollywood Helpline
On cusp of FDA and European decisions, Cytokinetics heart drug wins approval in China - The Business Journals
Cytokinetics' Hypertrophic Cardiomyopathy Treatment Approved in China - marketscreener.com
Cytokinetics rises after winning China approval for heart disease drug - TradingView — Track All Markets
Cytokinetics Wins China Approval For Myqorzo In Obstructive Hypertrophic Cardiomyopathy - Nasdaq
Cytokinetics (CYTK) Gains Approval for MYQORZO in China, Unlocks Milestone Payment - GuruFocus
Cytokinetics announces NMPA approval of Myqorzo® in China - marketscreener.com
Mirador Capital Partners LP Acquires 53,020 Shares of Cytokinetics, Incorporated $CYTK - MarketBeat
Cytokinetics Announces Nmpa Approval Of Myqorzo® In China - TradingView — Track All Markets
New heart drug in China approved to ease obstructive cardiomyopathy symptoms - Stock Titan
Sanders Morris Harris LLC Takes $1.18 Million Position in Cytokinetics, Incorporated $CYTK - MarketBeat
Insider Sell: Fady Malik Sells 2,200 Shares of Cytokinetics Inc (CYTK) - GuruFocus
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - The Manila Times
Bronstein, Gewirtz & Grossman, LLC Is Investigating Cytokinetics, Incorporated (CYTK) And Encourages Investors to Connect - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Cytokinetics, Incorporated (CYTK) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Frazier Life Sciences Management L.P. Invests $18.33 Million in Cytokinetics, Incorporated $CYTK - MarketBeat
Analysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK) and Regeneron (REGN) - The Globe and Mail
Needham & Company LLC Reaffirms "Buy" Rating for Cytokinetics (NASDAQ:CYTK) - MarketBeat
EMA’s CHMP backs new medicines from Hansoh, Cytokinetics - biocentury.com
Cytokinetics receives positive EU opinion for MYQORZO in heart condition By Investing.com - Investing.com Canada
Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Fortrea Holdings, Inc. ... - Bakersfield.com
Notice to Long-Term Shareholders of Cytokinetics, Inc. - GlobeNewswire
Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Fortrea Holdings, Inc. (NASDAQ: FTRE); Synopsys, Inc. (NASDAQ: SNPS); and WEBTOON Entertainment Inc. (NASDAQ: WBTN): Grabar Law Office Investigates Claims on Your Behalf - GlobeNewswire Inc.
CHMP recommends Immunitybio's Anktiva, Cytokinetics' Myqorzo - BioWorld MedTech
EMA committee recommends approval of Cytokinetics’ oHCM drug - Investing.com
Cytokinetics (CYTK) Receives Positive EU Recommendation for MYQO - GuruFocus
EMA committee recommends approval of Cytokinetics’ oHCM drug By Investing.com - Investing.com Australia
Cytokinetics receives positive EU opinion for MYQORZO in heart condition - Investing.com
Cytokinetics Receives Positive Opinion for MYQORZO® in EU - TradingView — Track All Markets
Cytokinetics Announces Positive CHMP Opinion Of MYQORZO For The Treatment Of Obstructive Hypertrophic Cardiomyopathy - TradingView — Track All Markets
Cytokinetics Announces Positive CHMP Opinion of MYQORZO® - GlobeNewswire
Cytokinetics (Nasdaq: CYTK) gains positive CHMP view on MYQORZO oHCM therapy, EU ruling expected in Q1 2026 - Stock Titan
Cytokinetics (CYTK) Stock Rating Reiterated at 'Buy' by Needham - GuruFocus
Cytokinetics, Incorporated (CYTK) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Cytokinetics, Incorporated (CYTK) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Notice For Long-Term Shareholders of Cytokinetics, Inc. - GlobeNewswire
Andrew Callos Sells 1,042 Shares of Cytokinetics (NASDAQ:CYTK) Stock - MarketBeat
Insider Selling: Andrew Callos Sells Shares of Cytokinetics Inc (CYTK) - GuruFocus
Callos Andrew, Cytokinetics EVP, sells $68,730 in shares - Investing.com
Foresite Capital Goes Bullish on Cytokinetics (CYTK), Snapping Up 458K Shares - sharewise.com
Norges Bank Invests $39.12 Million in Cytokinetics, Incorporated $CYTK - MarketBeat
Cytokinetics, Incorporated $CYTK Shares Bought by CW Advisors LLC - MarketBeat
Cytokinetics (CYTK) Valuation Check After Shareholder Investigation Into Aficamten FDA Review Disclosures - Yahoo Finance
Bronstein, Gewirtz & Grossman, LLC Encourages Cytokinetics, Incorporated (CYTK) Investors to Inquire about Securities Investigation - ACCESS Newswire
Is Shareholder Probe Into FDA Disclosures Reshaping the Investment Case for Cytokinetics’ Aficamten Story (CYTK)? - simplywall.st
Brown Advisory Inc. Has $32.89 Million Stake in Cytokinetics, Incorporated $CYTK - MarketBeat
Cytokinetics (NASDAQ:CYTK) EVP Sells $3,461,451.70 in Stock - MarketBeat
Callos Andrew, Cytokinetics EVP, sells $3.46m in stock By Investing.com - Investing.com South Africa
Insider Sell: Andrew Callos Sells 52,486 Shares of Cytokinetics Inc (CYTK) - GuruFocus
Callos Andrew, Cytokinetics EVP, sells $3.46m in stock - Investing.com India
Finanzdaten der Cytokinetics Inc-Aktie (CYTK)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.18%
0.62%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):